FDA approves OncoSil targeted radiation device for unresectable distal cholangiocarcinoma

The Humanitarian Device Exemption provides adults with unresectable, non-metastatic distal bile duct cancer with a new localised radiation option used alongside systemic therapy, although initial US use will be restricted to five centres participating in a post-approval study.

The US Food and Drug Administration (FDA) has granted Humanitarian Device Exemption approval to the OncoSil device for patients aged over 21 with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), for use as an adjunct to systemic therapy.

The authorisation makes OncoSil the first and only FDA-approved Class III device for dCCA, introducing an intratumoural radiation treatment for a rare cancer with limited treatment options.

Field	Content
Alert Type	Drug Approval
Drug Name	OncoSil
Indication	For patients aged over 21 with unresectable, non-metastatic distal cholangiocarcinoma, including locally advanced disease or disease otherwise unsuitable for surgery, for use as an adjunct to systemic therapy. (Proactive Investors)
Therapy Area(s)	Oncology; Biliary tract cancer; Interventional oncology
Geography	United States (FDA)
What Happened	The FDA has granted Humanitarian Device Exemption (HDE) approval to OncoSil Medical’s OncoSil device for adults aged over 21 with unresectable, non-metastatic distal cholangiocarcinoma. OncoSil uses radioactive phosphorus-32 microparticles implanted directly into the tumour under endoscopic ultrasound guidance to deliver localised radiation and is approved as an adjunct to systemic therapy. The decision completes the company’s HDE regulatory process and makes OncoSil the first and only FDA-approved Class III device for treatment of dCCA. (Proactive Investors)
Why It Matters	Distal cholangiocarcinoma is a rare and aggressive bile duct cancer, and more than half of patients are unable to undergo potentially curative surgery. The HDE provides eligible patients with an additional local treatment that can be used alongside systemic therapy, but the authorisation is based on the HDE standard of safety and probable benefit, and initial clinical use will remain restricted while further evidence is collected. (Proactive Investors)
Supporting Context	Around 8,000 people are diagnosed with cholangiocarcinoma annually in the US, with dCCA estimated to account for 30–40% of cases. OncoSil Medical estimates approximately 1,000 US patients annually could fall within the approved indication; its estimate of an A$80 million annual addressable market is a company commercial projection rather than part of the FDA’s assessment. (Proactive Investors)
Key Takeaway	FDA HDE approval introduces a localised intratumoural radiation option for adults with unresectable, non-metastatic distal cholangiocarcinoma who have limited treatment options.
What to Watch	Initial US distribution will be limited to five treatment centres participating in an FDA-required prospective post-approval study of 30 patients assessing safety and probable benefit, with follow-up for up to 24 months. OncoSil is targeting a US commercial launch during the second half of FY2027 while working on treatment-centre establishment, clinician training, reimbursement and market access. (Proactive Investors)
Primary Source	OncoSil Medical FDA HDE approval announcement
Relevant Date	16 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com